The aim of this study was to investigate, if anhedonia, a salient component of depression, shows similar response patterns to neurotransmitter challenge tests as depression, and if the two questionnaire based components Physical (PA) and Social (SA) Anhedonia can be discriminated by differences in drug related size and time of cortisol responses elicited by the specific serotonin (5- HT) and noradrenaline (NA) reuptake inhibitors citalopram and reboxetine and prolactin responses to the dopamine (DA) agonist bromocriptine orally applied to 36 male volunteers in a double blind balanced cross-over design. Analyses of variance applied to placebo corrected hormone responses revealed that low and late DA responses were characteristics of global Depression and of Physical Anhedonia, and that low DA responses were associated with high NA responses in PA, and with low 5-HT responses in SA. These patterns were explained by differences in transmitter production and receptor sensitivities and proved to be suitable to discriminate PA from SA and from global depression by analysing neurochemical response patterns rather than single means of variables.
Anderson, I. M., Ware, C. J., da Roza Davis, J. M., & Cowen, P. J. (1992). Decreased 5-HT-Mediated Prolactin Release in Major Depression. The British Journal of Psychiatry, 160, 372-378, http://dx.doi.org/10.1192/bjp.160.3.372
Arato, M., & Bagby, G. (1998). Gender Differences in m-CPP Challenge Tests in Healthy Volunteers. International Journal of Neuropsychopharmacology, 1, 121-124. http://dx.doi.org/10.1017/S1461145798001151
Asberg, M., Tr?skman, L., & Thoren, P. (1976). 5–HIAA in the Cerebrospinal Fluid: A Biochemical Suicide Predictor? Archives of General Psychiatry, 33, 1193-1197. http://dx.doi.org/10.1001/archpsyc.1976.01770100055005
Boadie, W., Dunlop, M. D., & Nemeroff, C. B. (2007). The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 64, 327-337. http://dx.doi.org/10.1001/archpsyc.64.3.327
Bond, A. J. (2001). Neurotransmitters, Temperament and Social Functioning. European Neuropsychopharmacology, 11, 261-274. http://dx.doi.org/10.1016/S0924-977X(01)00094-3
Chapman, L. J., Chapman, J. P., & Raulin, M. L. (1976). Scales for Physical and Social Anhedonia. Journal of Abnormal Psychology, 85, 374-382. http://dx.doi.org/10.1037/0021-843X.85.4.374
Charney, D. S., Heninger, G. R., Sternberg, D. E., Hafstad, K. M., Giddings, S., & Landis, D. H. (1982). Adrenergic Receptor Sensitivity in Depression. Effects of Clonidine in Depressed Patients and Healthy Subjects. Archives of General Psychiatry, 39, 290-294. http://dx.doi.org/10.1001/archpsyc.1982.04290030030005
Cleare, A. J., Murray, R. M., & O′Keane, V. (1996). Reduced Prolactin and Cortisol Responses to d-Fenfluramine in Depressed Compared to Healthy Matched Control Subjects. Neuropharmacology, 14, 349-354. http://dx.doi.org/10.1016/0893-133x(95)00144-3
Cohen, A. S., Najolia, G. M., Brown, L. A., & Minor, K. S. (2011). The State-Trait Disjunction of Anhedonia in Schizophrenia: Potential Affective, Cognitive and Social-Based Mechanisms. Clinical Psychology Review, 31, 440-448. http://dx.doi.org/10.1016/j.cpr.2010.11.001
Coupland, N., Glue, P., & Nutt, D. J. (1992). Challenge Tests of the Noradrenergic and GABA Ergic System in Depression and Anxiety. Molecular Aspects of Medicine, 13, 221-247. http://dx.doi.org/10.1016/0098-2997(92)90011-N
Dailly, E., Chenu, F., Renard, C. E., & Bourin, M. (2004). Dopamine, Depression and Antidepressants. Fundamental & Clinical Pharmacology, 18, 601-607. http://dx.doi.org/10.1111/j.1472-8206.2004.00287.x
Depue, R. A., Luciana, M., Arbisi, P., Collins, P., & Leon, A. (1994). Dopamine and the Structure of Personality: Relation of Agonist-Induced Dopamine Activity to Positive Emotionality. Journal of Personality and Social Psychology, 67, 485-498. http://dx.doi.org/10.1037/0022-3514.67.3.485
Docherty, A. R., & Sponheim, S. R. (2008). Anhedonia as a Phenotype for the Val158Met COMT Polymorphism in Relatives of Patients with Schizophrenia. Journal of Abnormal Psychology, 117, 88-98. http://dx.doi.org/10.1037/a0013745
Eysenck, H. J. (1967). The Biological Basis of Personality. Springfield, IL: Thomas.
Gerra, G., Zaimovic, A., Timpano, M., Zambelli, U., Delsignore, R., & Brambilla, F. (2000). Neuroendocrine Correlates of Temperamental Traits in Humans. Psychoneuroendocrinology, 25, 479-496. http://dx.doi.org/10.1016/S0306-4530(00)00004-4
Gutkovich, Z., Morrissey, R. F., Espaillat, R. K., & Dicker, R. (2011). Anhedonia and Pessimism in Hospitalized Depressed Adolescents. Depression Research and Treatment, 2011, Article ID: 795173. http://dx.doi.org/10.1155/2011/795173
Hansenne, M., Pinto, E., Pitchot, W., Reggers, J., Scantamburlo, G., Moor, M., & Ansseau, M. (2002). Further Evidence on the Relationship between Dopamine and Novelty Seeking: A Neuroendocrine Study. Personality and Individual Differences, 33, 967-977. http://dx.doi.org/10.1016/S0191-8869(01)00205-7
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004). Discovering Endophenotypes for Major Depression. Neuropsychopharmacology, 29, 1765-1781. http://dx.doi.org/10.1038/sj.npp.1300506
Hennig, J., Lange, N., Haag, A., Rohrmann, S., & Netter, P. (2000). Reboxetine in a Neuroendocrine Challenge Paradigm: Evidence for High Cortisol Responses in Healthy Volunteers Scoring High on Subclinical Depression. International Journal of Neuropsychopharmacology, 3, 193-201. http://dx.doi.org/10.1017/S1461145700002029
Hennig, J., & Netter, P. (2005). Neurotransmitter und Pers?nlichkeit [Neurotransmitters and Personality]. In J. Hennig, & P. Netter (Eds.), Biopsychologische Grundlagen der Pers?nlichkeit [Biopsychological Basis of Personality] (pp. 191-290). Munich: Spektrum/Elsevier. http://dx.doi.org/10.1007/978-3-8274-3089-2_3
Hetzel, G. O., Moeller, A., Erfurth, N., Michael, M., Rothermundt, V., Arolt, S., & Evers, S. (2004). The Impact of Selective Monoamine Reuptake Inhibitors Reboxetine and Citalopram on Visually-Evoked Event Related Potentials in Depressed Patients. Pharmacopsychiatry, 37, 200-205. http://dx.doi.org/10.1055/s-2004-827244
Insel, T. R., & Siever, L. J. (1981). The Dopamine System Challenge in Affective Disorders: A Review of Behavbioral and Neuroendocrine Responses. Journal of Clinical Psychopharmacology, 1, 207-213. http://dx.doi.org/10.1097/00004714-198107000-00005
Juckel, G. L., Sass, L., & Heinz, A. (2003). Anhedonia, Self-Experience in Schizophrenia, and Implications for Treatment. Pharmacopsychiatry, 36, 176-180. http://dx.doi.org/10.1055/s-2003-45127
Kuha, A., Suvisaari, J., Per?l?, J., Eerola, M., Saarni, S. S., Partonen, T., L?nnqvist, J., & Tuulio-Henriksson, A. (2011). Associations of Anhedonia and Cognition in Persons with Schizophrenia Spectrum Disorders, Their Siblings, and Controls. Journal of Nervous and Mental Disease, 199, 30-37. http://dx.doi.org/10.1097/NMD.0b013e3182043a6d
Lemke, M. R., Puhl, P., Koethe, N., & Winkler, T. (1999). Psychomotor Retardation and Anhedonia in Depression. Acta Psychiatrica Scandinavica, 99, 252-256. http://dx.doi.org/10.1111/j.1600-0447.1999.tb07221.x
Lesch, K. P., Laux, G., Erb, A., Pfuller, H., & Beckmann, H. (1988). Growth Hormone (GH) Responses to GH-Releasing Hormone in Depression: Correlation with GH Release Following Clonidine. Psychiatry Research, 25, 301-310. http://dx.doi.org/10.1016/0165-1781(88)90100-X
Livesley, W. J. (1998). Suggestions for a Framework for an Empirically Based Classification of Personality Disorder. Canadian Journal of Psychiatry, 43, 1-23.
Lotrich, F. E., Bies, R., Muldoon, M. F., Manuck, S. B., Smith, G. S., & Pollock, B. G. (2005). Neuroendocrine Response to Intravenous Citalopram in Healthy Control Subjects. Pharmacokinetic Influences. Psychopharmacology, 178, 268-275. http://dx.doi.org/10.1007/s00213-004-2006-4
Mattos, P. V., Franco, A., Noel, F., Segenreich, D., & Gon?alves, J. C. (2006). Usefulness of Serotoninergic Challenge with Oral Citalopram. Revista Brasileira di Psiquiatrica, 28, 203-205. http://dx.doi.org/10.1590/S1516-44462006000300011
Mongeau, R., Blier, P. C., & de Montigny, C. (1997). The Serotonergic and Noradrenergic Systems of the Hippocampus: Their Interactions and the Effects of Antidepressant Treatments. Brain Research Reviews, 23, 145-195. http://dx.doi.org/10.1016/S0165-0173(96)00017-3
Nakonezny, P. A. T., Carmody, J., Morris, D. W., Kurian, B. T., & Trivedi, M. H. (2010). Psychometric Evaluation of the Snaith-Hamilton Pleasure Scale in Adult Outpatients with Major Depressive Disorder. International Clinical Psychopharmacology, 25, 328-333. http://dx.doi.org/10.1097/YIC.0b013e32833eb5ee
Netter, P. (2006). Dopamine Challenge Tests as an Indicator of Psychological Traits. Human Psychopharmacology Clinical and Experimental, 21, 91-99. http://dx.doi.org/10.1002/hup.754
Netter, P., Reuter, M., & Hennig, J. (2004). Time of Onset of Hormone Responses to Challenge Tests, a Better Marker for Personality than Size of Responses? Journal of Physiology, 18, 241.
Nyberg, S., Nordstr?m, A. L., Halldin, C., & Farde, L. (1995). Positron Emission Tomography Studies on D2 Dopamine Receptor Occupancy and Plasma Antipsychotic Drug Levels in Man. International Clinical Psychopharmacology, 10, 81-85.
O’Keane, V., O’Hanlon, M., Webb, M., & Dinan, T. (1991). D-Fenfluramine/Prolactin Response throughout the Menstrual Cycle: Evidence for an Estrogen Induced Alteration. Clinical Endocrinology, 34, 289-292. http://dx.doi.org/10.1111/j.1365-2265.1991.tb03768.x
Papp, M., Klimek, V., & Willner, P. (1994). Parallel Changes in Dopamine D-sub-2 Receptor Binding in Limbic Forebrain Associated with Chronic Mild Stress-Induced Anhedonia and Its Reversal by Imipramine. Psychopharmacology, 115, 441-446. http://dx.doi.org/10.1007/BF02245566
Pitchot, W., Hansenne, M., Gonzalez Moreno, A., & Ansseau, M. (1992). Suicidal Behavior and Growth Hormone Response to Apomorphine Test. Biological Psychiatry, 31, 1213-1219. http://dx.doi.org/10.1016/0006-3223(92)90340-6
Power, A. C., & Cowen, P. J. (1992). Neuroendocrine Challenge Tests: Assessment of 5-HT Function in Anxiety and Depression. Molecular Aspects of Medicine, 13, 205-220. http://dx.doi.org/10.1016/0098-2997(92)90010-W
Pukrop, R., Sass, H., & Steinmeyer, E. M. (2000). Circumplex Models of the Similarity Relationships between Higher Order Factors of Personality and Personality Disorders. Comprehensive Psychiatry, 41, 438-445. http://dx.doi.org/10.1053/comp.2000.16558
Reul, J. M., & Holsboer, F. (2002). Corticotropin-Releasing Factor Receptors 1 and 2 in Anxiety and Depression. Current Opinion in Pharmacology, 2, 23-33. http://dx.doi.org/10.1016/S1471-4892(01)00117-5
Riederer, P., & Birkmayer, W. (1980). A New Concept: Brain Area Specific Imbalance of Neurotransmitters in Depression Syndrome-Human Brain Studies. In P. Riederer, & W. Birkmeayer (Eds.), Enzymes and Neurotransmitters in Mental Disease (pp. 261-278). New York: Wiley.
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2002). Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence. In S. F. Ali (Ed.), Cellular and Molecular Mechanisms of Drugs of Abuse. II: Cocaine, Substituted Amphetamines, GHB, and Opiates (pp. 109-126). New York: New York Academy of Sciences.
Ruegg, R. G., Gilmore, J., Ekstrom, R. D., Corrigan, M., Knight, B., Tancer, M., Leatherman, M. E., Carson, S. W., & Golden, R. N. (1997). Clomipramine Challenge Responses Covary with Tridimensional Personality Questionnaire Scores in Healthy Subjects. Biological Psychiatry, 42, 1123-1129. http://dx.doi.org/10.1016/S0006-3223(97)00009-7
Schüle, C., Baghai, T., Schmidbauer, S., Bidlingmaier, M., Strasburger, C. J., & Laakmann, G. (2004). Reboxetine Acutely Stimulates Cortisol, ACTH, Growth Hormone and Prolactin Secretion in Healthy Male Subjects. Psychoneuroendocrinology, 29, 185-2004. http://dx.doi.org/10.1016/S0306-4530(03)00022-2
Shah, P. J., Ogilvie, A. D., Goodwin, G. M., & Ebmeier, K. O. (1997). Clinical and Psychometric Correlates of Dopamine D-2 Binding in Depression. Psychological Medicine, 27, 1247-1256. http://dx.doi.org/10.1017/S0033291797005382
Shelton, R. A., & Tomarken, J. (2001). Can Recovery from Depression Be Achieved? Psychiatric Services, 52, 1469-1478. http://dx.doi.org/10.1176/appi.ps.52.11.1469
Snaith, P. (1993). Anhedonia: A Neglected Symptom of Psychopathology. Psychological Medicine, 23, 957-966. http://dx.doi.org/10.1017/S0033291700026428
Stein, D. J. (2008). Depression, Anhedonia, and Psychomotor Symptoms: The Role of Dopaminergic Neurocircuitry. CNS Spectrums, 13, 561-565.
Van de Kar, L. D. (1998). Methods in Neuroendocrinology. Boca Raton, FL: CRC Press.
Von Zerssen, D., & Koeller, D. M. (1976). Depressivit?tsskala: Manual [Depression Scale: Manual]. Weinheim: Beltz Test Gesellschaft.
Widiger, T. A. (2011). Personality and Psychopathology. World Psychiatry, 10, 103-106. http://dx.doi.org/10.1002/j.2051-5545.2011.tb00024.x
Willner, P. (1995). Pharmacology of Anhedonia. European Neuropsychopharmacology, 5, 214. http://dx.doi.org/10.1016/0924-977X(95)90243-7
Willner, P. (2005). Chronic Mild Stress Revisited: Consistency and Behavioural Neurobiological Concordance in the Effects of CMS. Neuropsychobiology, 52, 90-110. http://dx.doi.org/10.1159/000087097
Wolf, D. H. (2006). Anhedonia in Schizophrenia. Current Psychiatry Reports, 8, 322-328. http://dx.doi.org/10.1007/s11920-006-0069-0
Yatham, L. N., & Steiner, M. (1993). Neuroendocrine Probes of Serotonergic Function: A Critical Review. Life Sciences, 53, 447-463. http://dx.doi.org/10.1016/0024-3205(93)90696-Z